Skin Neoplasms

The grounding supports malignant transformation of melanocytes as the cause of melanoma, a key skin neoplasm subtype. It also indicates that genomic alterations in signaling pathways such as MAPK and PI3K contribute to development and progression.

The literature describes skin neoplasm biology, especially melanoma, as involving altered signal transduction and gene expression regulation in oncogenic pathways. Tumor cells interact with the tumor microenvironment and the immune system, and tumor-infiltrating lymphocytes are discussed as part of the immune response to these tumors.

The supplied grounding does not provide specific risk factors for skin neoplasms beyond the presence of advanced or unresectable disease categories in melanoma literature. It does note that BRAF mutations are common in advanced melanoma, but this is a molecular feature rather than a general risk factor.

Management described in the grounding includes surgery for primary melanoma, followed by adjuvant therapy or clinical trial enrollment in higher-risk disease. Systemic treatment categories highlighted include immune checkpoint inhibitors, BRAF-targeted therapy, MEK inhibitors, chemotherapy, cytokine therapy, and interferon-based or vaccine-based adjuvant approaches.